Feng-Ming Hsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Feng-Ming Hsu has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
- Jason Chia-Hsien Cheng
Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
21 shared publications - Chiao-Ling Tsai
Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
9 shared publications - Jang-Ming Lee
Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan
9 shared publications - Chih-Hung Hsu
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
7 shared publications Wen-Chi Yang
Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital , Taipei, (Y.-L.C., S.-F.L., W.-C.Y., S.-L.L., F.-M.H.)
6 shared publications- Ya-Fang Chen
Department of Medical Imaging, National Taiwan University Hospital, Taipei
6 shared publications
Latest Publications
- 16 October 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Unilateral vs bilateral hippocampal avoidance during whole-brain radiotherapy with memantine for brain metastases: A randomized single-blind phase 2 clinical trial
Background: Hippocampal avoidance whole-brain radiotherapy (HA-WBRT) with memantine reduces, but does not eliminate, cognitive decline. Left hippocampal dose may be more closely associated with cognitive outcomes. We investigated whether unilateral (left) HA-WBRT is equivalent to bilateral HA-WBRT for neurocognitive function. Methods: In this randomized, single-blind, phase 2 equivalence trial, patients with brain metastases were assigned 1:1 to unilateral (left) or bilateral HA-WBRT (30 Gy in 10 fractions) with concurrent memantine. The primary endpoint was relative decline in Hopkins Verbal Learning Test-Revised (HVLT-R) memory score from baseline to 6 months; equivalence required the 90% CI for the between-arm difference to fall within ±15 percentage points. Results: Among 73 patients (unilateral, n = 36; bilateral, n = 37; median follow-up, 13.2 months), mean 6-month relative HVLT-R decline was 4.75% versus 5.05% (difference, −0.31 percentage points; 90% CI, −12.02 to 11.40 percentage points; TOST P = .02), meeting the equivalence criterion. Brain progression-free survival (10.3 vs 10.8 months; P = .96), overall survival (17.8 vs 12.8 months; P = .94), acute toxicity (≥grade 2, 44.4% vs 35.1%; P = .43), and 6-month neurocognitive failure (61.1% vs 56.8%; Gray test P = .78) were similar. Global health status appeared more stable with unilateral HA-WBRT (interaction, P < .001). Exploratory plasma brain-derived neurotrophic factor (BDNF) trajectories varied by neurocognitive failure status (FDR q = .09). Conclusions: Unilateral (left) HA-WBRT with memantine met the prespecified equivalence criterion for verbal memory, with comparable oncologic outcomes and safety; non-verbal memory was not assessed. These findings warrant validation, particularly when bilateral avoidance is challenging.
- 16 October 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Unilateral vs bilateral hippocampal avoidance during whole-brain radiotherapy with memantine for brain metastases: A randomized single-blind phase 2 clinical trial
Background: Hippocampal avoidance whole-brain radiotherapy (HA-WBRT) with memantine reduces, but does not eliminate, cognitive decline. Left hippocampal dose may be more closely associated with cognitive outcomes. We investigated whether unilateral (left) HA-WBRT is equivalent to bilateral HA-WBRT for neurocognitive function. Methods: In this randomized, single-blind, phase 2 equivalence trial, patients with brain metastases were assigned 1:1 to unilateral (left) or bilateral HA-WBRT (30 Gy in 10 fractions) with concurrent memantine. The primary endpoint was relative decline in Hopkins Verbal Learning Test-Revised (HVLT-R) memory score from baseline to 6 months; equivalence required the 90% CI for the between-arm difference to fall within ±15 percentage points. Results: Among 73 patients (unilateral, n = 36; bilateral, n = 37; median follow-up, 13.2 months), mean 6-month relative HVLT-R decline was 4.75% versus 5.05% (difference, −0.31 percentage points; 90% CI, −12.02 to 11.40 percentage points; TOST P = .02), meeting the equivalence criterion. Brain progression-free survival (10.3 vs 10.8 months; P = .96), overall survival (17.8 vs 12.8 months; P = .94), acute toxicity (≥grade 2, 44.4% vs 35.1%; P = .43), and 6-month neurocognitive failure (61.1% vs 56.8%; Gray test P = .78) were similar. Global health status appeared more stable with unilateral HA-WBRT (interaction, P < .001). Exploratory plasma brain-derived neurotrophic factor (BDNF) trajectories varied by neurocognitive failure status (FDR q = .09). Conclusions: Unilateral (left) HA-WBRT with memantine met the prespecified equivalence criterion for verbal memory, with comparable oncologic outcomes and safety; non-verbal memory was not assessed. These findings warrant validation, particularly when bilateral avoidance is challenging.
- 27 October 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (2) , 495-504
Elective versus involved target volume definition of stereotactic spine radiosurgery for spinal metastases: A phase II randomized clinical trial
Background: With the growing adoption of stereotactic spine radiosurgery (SSRS), precise target delineation is essential. The International Spine Radiosurgery Consortium (ISRC) has proposed contouring guidelines covering both the tumor and adjacent structures, termed the elective field (EF). We designed this randomized trial comparing EF and involved field (IF)-contouring strategy to determine which yielded the lowest protocol-specified failure rate. Methods: Patients with spinal metastases not requiring surgery were randomized 1:1 to receive 16 Gy in a single fraction via EF or IF SSRS. EF followed ISRC recommendations. IF comprised the gross tumor volume with an 8-mm isotropic intraosseous margin. We aimed to reject failure rates >10% at 6 months. Treatment failure was defined as grade ≥3 treatment-related toxicity or local progression. Results: Between August 2019 and May 2024, 106 patients (164 segments) were analyzed. Fifty-two and 54 patients were randomized to EF and IF, respectively. The median follow-up was 41.6 months. At 6 months, the cumulative incidence of treatment failure (CIF) met the acceptability criteria (per-patient: EF 3.8% vs IF 7.5%, P = .42). By 12 months, EF group showed low CIF, both per-patient (3.8% vs 13.5%) and per-segment (2.6% vs 11.8%). CIF curves differed significantly between groups (Gray’s test, per-patient: P = .03, per-segment: P = .02). In the IF group, two-thirds of the out-of-field or marginal recurrences could be enclosed by the EF contouring strategy. Conclusions: EF and IF SSRS met the criteria for acceptable CIF at 6 months. With longer follow-up, EF demonstrated lower failure rates. ISRC contouring guidelines should be the standard practice.
- 27 October 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (2) , 495-504
Elective versus involved target volume definition of stereotactic spine radiosurgery for spinal metastases: A phase II randomized clinical trial
Background: With the growing adoption of stereotactic spine radiosurgery (SSRS), precise target delineation is essential. The International Spine Radiosurgery Consortium (ISRC) has proposed contouring guidelines covering both the tumor and adjacent structures, termed the elective field (EF). We designed this randomized trial comparing EF and involved field (IF)-contouring strategy to determine which yielded the lowest protocol-specified failure rate. Methods: Patients with spinal metastases not requiring surgery were randomized 1:1 to receive 16 Gy in a single fraction via EF or IF SSRS. EF followed ISRC recommendations. IF comprised the gross tumor volume with an 8-mm isotropic intraosseous margin. We aimed to reject failure rates >10% at 6 months. Treatment failure was defined as grade ≥3 treatment-related toxicity or local progression. Results: Between August 2019 and May 2024, 106 patients (164 segments) were analyzed. Fifty-two and 54 patients were randomized to EF and IF, respectively. The median follow-up was 41.6 months. At 6 months, the cumulative incidence of treatment failure (CIF) met the acceptability criteria (per-patient: EF 3.8% vs IF 7.5%, P = .42). By 12 months, EF group showed low CIF, both per-patient (3.8% vs 13.5%) and per-segment (2.6% vs 11.8%). CIF curves differed significantly between groups (Gray’s test, per-patient: P = .03, per-segment: P = .02). In the IF group, two-thirds of the out-of-field or marginal recurrences could be enclosed by the EF contouring strategy. Conclusions: EF and IF SSRS met the criteria for acceptable CIF at 6 months. With longer follow-up, EF demonstrated lower failure rates. ISRC contouring guidelines should be the standard practice.
- 31 January 2025
- Published by Elsevier in The Spine Journal
- Vol. 25 (7) , 1360-1370
Single versus multiple fraction stereotactic spine radiosurgery for spinal metastases: a prospective randomized Phase II trial
- 31 January 2025
- Published by Elsevier in The Spine Journal
- Vol. 25 (7) , 1360-1370
Single versus multiple fraction stereotactic spine radiosurgery for spinal metastases: a prospective randomized Phase II trial
- Open Access
- 31 December 2023
- Published by The Korean Spinal Neurosurgery Society in Neurospine
- Vol. 20 (4) , 1431-1442
Delay of Surgery for Spinal Metastasis due to the COVID-19 Outbreak Affected Patient Outcomes
Objective: The present study is to analyze the effects of the coronavirus disease 2019 (COVID 2019) outbreak and the subsequent lockdown on the outcomes of spinal metastasis patients.Methods: The study was a retrospective analysis of data from a prospective cohort study. All patients underwent surgical intervention for spinal metastases between January 2019 and December 2021 and had at least 3 months of postoperative follow-up. The primary outcome was overall mortality during the 4 different stages (pre-COVID-19 era, COVID-19 pandemic except in Taiwan, national lockdown, lifting of the lockdown). The secondary outcomes were the oncological severity scores, medical/surgical accessibility, and patient functional outcome during the 4 periods as well as survival/mortality.Results: A total of 233 patients were included. The overall mortality rate was 41.20%. During the Taiwan lockdown, more patients received palliative surgery than other surgical methods, and no total en bloc spondylectomy was performed. The time from surgeon visit to operation was approximately doubled after the COVID-19 outbreak in Taiwan (75.97, 86.63, 168.79, and 166.91 hours in the 4 periods, respectively). The estimated survival probability was highest after the national lockdown was lifted and lowest during the lockdown. In the multivariate analysis, increased risk of mortality was observed with delay of surgery, with emergency surgery having a higher risk with delays above 33 hours, urgent surgery (below 59 and above 111 hours), and elective surgery (above 332 hours).Conclusion: The COVID-19 pandemic and related policies have altered daily clinical practice and negatively impacted the survival of patients with spinal metastases.
- 31 December 2023
- Published by The Korean Spinal Neurosurgery Society in Neurospine
- Vol. 20 (4) , 1431-1442
Open AccessDelay of Surgery for Spinal Metastasis due to the COVID-19 Outbreak Affected Patient Outcomes
Objective: The present study is to analyze the effects of the coronavirus disease 2019 (COVID 2019) outbreak and the subsequent lockdown on the outcomes of spinal metastasis patients.Methods: The study was a retrospective analysis of data from a prospective cohort study. All patients underwent surgical intervention for spinal metastases between January 2019 and December 2021 and had at least 3 months of postoperative follow-up. The primary outcome was overall mortality during the 4 different stages (pre-COVID-19 era, COVID-19 pandemic except in Taiwan, national lockdown, lifting of the lockdown). The secondary outcomes were the oncological severity scores, medical/surgical accessibility, and patient functional outcome during the 4 periods as well as survival/mortality.Results: A total of 233 patients were included. The overall mortality rate was 41.20%. During the Taiwan lockdown, more patients received palliative surgery than other surgical methods, and no total en bloc spondylectomy was performed. The time from surgeon visit to operation was approximately doubled after the COVID-19 outbreak in Taiwan (75.97, 86.63, 168.79, and 166.91 hours in the 4 periods, respectively). The estimated survival probability was highest after the national lockdown was lifted and lowest during the lockdown. In the multivariate analysis, increased risk of mortality was observed with delay of surgery, with emergency surgery having a higher risk with delays above 33 hours, urgent surgery (below 59 and above 111 hours), and elective surgery (above 332 hours).Conclusion: The COVID-19 pandemic and related policies have altered daily clinical practice and negatively impacted the survival of patients with spinal metastases.
- Open Access
- 4 January 2023
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Topoisomerase I Inhibition Radiosensitizing Hepatocellular Carcinoma by RNF144A-mediated DNA-PKcs Ubiquitination and Natural Killer Cell Cytotoxicity
Topoisomerase I (TOP1) participates the repair of DNA double-strand breaks (DSBs) upon radiation therapy (RT). RNF144A mediates ubiquitination of catalytic subunit of DNA protein kinase (DNA-PKcs), a critical factor in DSB repair. This study aimed to investigate the natural killer (NK) cell-mediated radiosensitization with TOP1 inhibition and the mechanism by DNA-PKcs/RNF144A.
- 4 January 2023
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Open AccessTopoisomerase I Inhibition Radiosensitizing Hepatocellular Carcinoma by RNF144A-mediated DNA-PKcs Ubiquitination and Natural Killer Cell Cytotoxicity
Topoisomerase I (TOP1) participates the repair of DNA double-strand breaks (DSBs) upon radiation therapy (RT). RNF144A mediates ubiquitination of catalytic subunit of DNA protein kinase (DNA-PKcs), a critical factor in DSB repair. This study aimed to investigate the natural killer (NK) cell-mediated radiosensitization with TOP1 inhibition and the mechanism by DNA-PKcs/RNF144A.
- 5 September 2022
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 175, 159-166
Prognostic significance of lab data and performance comparison by validating survival prediction models for patients with spinal metastases after radiotherapy
- 5 September 2022
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 175, 159-166
Prognostic significance of lab data and performance comparison by validating survival prediction models for patients with spinal metastases after radiotherapy
- Open Access
- 1 December 2021
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 120 (12) , 2176-2185
A retrospective study of clinicopathologic and molecular features of inoperable early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy
- 1 December 2021
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 120 (12) , 2176-2185
Open AccessA retrospective study of clinicopathologic and molecular features of inoperable early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy
- Open Access
- 2 October 2021
- Published by MDPI AG in Applied Sciences
- Vol. 11 (19) , 9180
Deep Learning-Based Segmentation of Various Brain Lesions for Radiosurgery
Semantic segmentation of medical images with deep learning models is rapidly being developed. In this study, we benchmarked state-of-the-art deep learning segmentation algorithms on our clinical stereotactic radiosurgery dataset. The dataset consists of 1688 patients with various brain lesions (pituitary tumors, meningioma, schwannoma, brain metastases, arteriovenous malformation, and trigeminal neuralgia), and we divided the dataset into a training set (1557 patients) and test set (131 patients). This study demonstrates the strengths and weaknesses of deep-learning algorithms in a fairly practical scenario. We compared the model performances concerning their sampling method, model architecture, and the choice of loss functions, identifying suitable settings for their applications and shedding light on the possible improvements. Evidence from this study led us to conclude that deep learning could be promising in assisting the segmentation of brain lesions even if the training dataset was of high heterogeneity in lesion types and sizes.
- 2 October 2021
- Published by MDPI AG in Applied Sciences
- Vol. 11 (19) , 9180
Open AccessDeep Learning-Based Segmentation of Various Brain Lesions for Radiosurgery
Semantic segmentation of medical images with deep learning models is rapidly being developed. In this study, we benchmarked state-of-the-art deep learning segmentation algorithms on our clinical stereotactic radiosurgery dataset. The dataset consists of 1688 patients with various brain lesions (pituitary tumors, meningioma, schwannoma, brain metastases, arteriovenous malformation, and trigeminal neuralgia), and we divided the dataset into a training set (1557 patients) and test set (131 patients). This study demonstrates the strengths and weaknesses of deep-learning algorithms in a fairly practical scenario. We compared the model performances concerning their sampling method, model architecture, and the choice of loss functions, identifying suitable settings for their applications and shedding light on the possible improvements. Evidence from this study led us to conclude that deep learning could be promising in assisting the segmentation of brain lesions even if the training dataset was of high heterogeneity in lesion types and sizes.
- Open Access
- 7 August 2021
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 23 (12) , 2125
Erratum to: Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial
In the originally published version of this manuscript, the affiliation ‘Graduate Institute of Oncology (W-C.Y., J.C-H.C., S-H.K., F-M.H.) and Cancer Research Center (W-C.Y., J.C-H.C., S-H.K., F-M.H.)’ was incomplete. It has now been updated as follows: ‘Graduate Institute of Oncology (W-C.Y., J.C-H.C., S-H.K., F-M.H.) and Cancer Research Center (W-C.Y., J.C-H.C., S-H.K., F-M.H.), National Taiwan University College of Medicine, Taipei, Taiwan’. In addition, in Table 1, item Primary cancer of the HA-WBRT group, the number of “Others: 3.0% (33)”, has been corrected to “Others: 3.0% (1)”.
- 7 August 2021
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 23 (12) , 2125
Open AccessErratum to: Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial
In the originally published version of this manuscript, the affiliation ‘Graduate Institute of Oncology (W-C.Y., J.C-H.C., S-H.K., F-M.H.) and Cancer Research Center (W-C.Y., J.C-H.C., S-H.K., F-M.H.)’ was incomplete. It has now been updated as follows: ‘Graduate Institute of Oncology (W-C.Y., J.C-H.C., S-H.K., F-M.H.) and Cancer Research Center (W-C.Y., J.C-H.C., S-H.K., F-M.H.), National Taiwan University College of Medicine, Taipei, Taiwan’. In addition, in Table 1, item Primary cancer of the HA-WBRT group, the number of “Others: 3.0% (33)”, has been corrected to “Others: 3.0% (1)”.
- 7 June 2021
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 153 (3) , 455-465
Peri-radiosurgical administration of bevacizumab improves radiographic response to single and fractionated stereotactic radiosurgery for large brain metastasis
Introduction Stereotactic radiosurgery (SRS) is a standard of care for brain metastases (BM) patients, yet large BM are at a greater risk for radionecrosis and local progression (LP). Concomitant bevacizumab and radiotherapy has been shown to improve outcomes in primary and metastatic brain tumors. This retrospective study investigated the efficacy and safety of concurrent bevacizumab and SRS for large BM. Methods From 2015 to 2019, patients with a BM diameter ≥ 2 cm who received either combination therapy (n = 49, SRS + BVZ group), or SRS alone (n = 73, SRS group) were enrolled. Bevacizumab was given peri-radiosurgically with a 2-week interval. Radiographic response was assessed using the RECIST version 1.1. Competing risk and logistic regression analysis were performed to evaluate prognostic factors. Results Radiographic response was achieved in 41 patients (84%) in the SRS + BVZ group and 37 patients (51%) in the SRS group (p = 0.001). In the multivariate regression analysis, concurrent bevacizumab was independently associated with a better radiographic response (p = 0.003). The cumulative incidences of LP and ≥ grade 2 radionecrosis at 12 months between the SRS + BVZ group and SRS group were 2% versus 6.8%, and 14.3% versus 14.6%, respectively. For patients with BM size ≥ 3 cm, the cumulative incidence of LP was significantly lower in the SRS + BVZ group (p = 0.03). No ≥ grade 4 toxicity was observed in either group. Conclusions Concurrent bevacizumab and SRS for large BM is highly effective, with a better radiographic response and minimal excessive treatment-related toxicities. Peri-radiosurgical bevacizumab preferentially reduced the risk of LP, especially for BM size ≥ 3 cm.
- 7 June 2021
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 153 (3) , 455-465
Peri-radiosurgical administration of bevacizumab improves radiographic response to single and fractionated stereotactic radiosurgery for large brain metastasis
Introduction Stereotactic radiosurgery (SRS) is a standard of care for brain metastases (BM) patients, yet large BM are at a greater risk for radionecrosis and local progression (LP). Concomitant bevacizumab and radiotherapy has been shown to improve outcomes in primary and metastatic brain tumors. This retrospective study investigated the efficacy and safety of concurrent bevacizumab and SRS for large BM. Methods From 2015 to 2019, patients with a BM diameter ≥ 2 cm who received either combination therapy (n = 49, SRS + BVZ group), or SRS alone (n = 73, SRS group) were enrolled. Bevacizumab was given peri-radiosurgically with a 2-week interval. Radiographic response was assessed using the RECIST version 1.1. Competing risk and logistic regression analysis were performed to evaluate prognostic factors. Results Radiographic response was achieved in 41 patients (84%) in the SRS + BVZ group and 37 patients (51%) in the SRS group (p = 0.001). In the multivariate regression analysis, concurrent bevacizumab was independently associated with a better radiographic response (p = 0.003). The cumulative incidences of LP and ≥ grade 2 radionecrosis at 12 months between the SRS + BVZ group and SRS group were 2% versus 6.8%, and 14.3% versus 14.6%, respectively. For patients with BM size ≥ 3 cm, the cumulative incidence of LP was significantly lower in the SRS + BVZ group (p = 0.03). No ≥ grade 4 toxicity was observed in either group. Conclusions Concurrent bevacizumab and SRS for large BM is highly effective, with a better radiographic response and minimal excessive treatment-related toxicities. Peri-radiosurgical bevacizumab preferentially reduced the risk of LP, especially for BM size ≥ 3 cm.